Wednesday, July 8, 2026

pharma · Multiple Myeloma · Ovarian Cancer · CASIF

CASI Pharmaceuticals

CASI Pharmaceuticals is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker CASIF. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer, Advanced Cancer, Recurren

601 Gateway Blvd, San Francisco, CA 94080, US HQ
44 Employees
Public company Type
CASIF · NYSE Ticker
Company details
Status
Public
HQ
601 Gateway Blvd, San Francisco, CA 94080, US
Employees
44
Programs
22
Drugs
11
Patents
2
Clinical program

Panzem NCD

Phase 2 · small molecule · Recurrent Glioblastoma Multiforme

Panzem NCD for Recurrent Glioblastoma Multiforme is a Phase 2 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All CASI Pharmaceuticals projects Phase 2 small molecule completed

Internal code ME-CLN-007

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CASI Pharmaceuticals
Phase
Phase 2
Modality
small_molecule
Indication
Recurrent Glioblastoma Multiforme
Status
completed
Trials
1

Clinical trials